Natalizumab in the pediatric MS population: Results of the Italian registry

Angelo Ghezzi; Lucia Moiola; Carlo Pozzilli; Vincenzo Brescia-Morra; Paolo Gallo; Luigi Maria Edoardo Grimaldi; Massimo Filippi; Giancarlo Comi G.

doi:10.1186/s12883-015-0433-y

Natalizumab in the pediatric MS population: Results of the Italian registry

Angelo Ghezzi, Lucia Moiola, Carlo Pozzilli, Vincenzo Brescia-Morra, Paolo Gallo, Luigi Maria Edoardo Grimaldi, Massimo Filippi, Giancarlo Comi G.

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p

Original language	English
Article number	174
Journal	BMC Neurology
Volume	15
Issue number	1
DOIs	https://doi.org/10.1186/s12883-015-0433-y
Publication status	Published - Sep 25 2015

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1186/s12883-015-0433-y

Fingerprint Dive into the research topics of 'Natalizumab in the pediatric MS population: Results of the Italian registry'. Together they form a unique fingerprint.

Cite this

Ghezzi, A., Moiola, L., Pozzilli, C., Brescia-Morra, V., Gallo, P., Grimaldi, L. M. E., Filippi, M., & G., G. C. (2015). Natalizumab in the pediatric MS population: Results of the Italian registry. BMC Neurology, 15(1), [174]. https://doi.org/10.1186/s12883-015-0433-y

@article{dfc69502e8ac40138d1a3396131c6383,

title = "Natalizumab in the pediatric MS population: Results of the Italian registry",

abstract = "Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p",

author = "Angelo Ghezzi and Lucia Moiola and Carlo Pozzilli and Vincenzo Brescia-Morra and Paolo Gallo and Grimaldi, {Luigi Maria Edoardo} and Massimo Filippi and G., {Giancarlo Comi}",

year = "2015",

month = sep,

day = "25",

doi = "10.1186/s12883-015-0433-y",

language = "English",

volume = "15",

journal = "BMC Neurology",

issn = "1471-2377",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Natalizumab in the pediatric MS population

T2 - Results of the Italian registry

AU - Ghezzi, Angelo

AU - Moiola, Lucia

AU - Pozzilli, Carlo

AU - Brescia-Morra, Vincenzo

AU - Gallo, Paolo

AU - Grimaldi, Luigi Maria Edoardo

AU - Filippi, Massimo

AU - G., Giancarlo Comi

PY - 2015/9/25

Y1 - 2015/9/25

N2 - Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p

AB - Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p

UR - http://www.scopus.com/inward/record.url?scp=84942155555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942155555&partnerID=8YFLogxK

U2 - 10.1186/s12883-015-0433-y

DO - 10.1186/s12883-015-0433-y

M3 - Article

AN - SCOPUS:84942155555

VL - 15

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

IS - 1

M1 - 174

ER -